Gene therapy candidate clears FDA hurdle
According to 4D Molecular Therapeutics, it has received FDA Clearance of an IND Application for 4D-150, a dual-transgene intravitreal gene therapy for patients with wet AMD.
Unity Biotechnology announces positive data from Phase 1 trial of UBX1325
Investigators found evidence of improvement in vision and retinal structure in patients with DME and AMD sustained through 12 weeks.
Companies announce eye care collaboration
AbbVie and REGENXBIO announced a strategic partnership to develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases.
Early Phase 2 data with high-dose aflibercept promising in wet AMD
Regeneron Pharmaceuticals announced at an ongoing Phase 2 trial has met its primary safety endpoint with no new safety signals observed.
Wet AMD: Current therapies and treatment
Experts discuss durability of action and atrophy inhibitor among primary treatment goals.
An Overview of Age-Related Macular Degeneration
Key opinion leaders in ophthalmology provide an overview of age-related macular degeneration and comment on clinical recommendations for assessing symptoms.
Results of dry AMD pilot study show promise
LumiThera has announced positive interim data in visual and ERG clinical outcomes in the ELECTROLIGHT pilot study in dry AMD patients.
Addressing the gaps in AMD treatment
Aleksandra Rachitskaya, MD, speaks on the current gaps in AMD treatment as well as ongoing retinal advancements to help address unmeet needs of patients.
Emerging therapies in AMD management
Anat Loewenstein, MD, provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD.
Identifying 3 major risk factors for AMD
Joshua Mali, MD, discusses the three major risk factors for developing age-related macular degeneration (AMD).
Learning the basics of AMD
Ian C. Han, MD, dives into the basics of age-related macular degeneration (AMD) and what patients need to know.
2 Clarke Drive Cranbury, NJ 08512